Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition provides Merck KGaA a drug prepared for a pivotal check within the blood dysfunction polycythemia vera. Silence’s RNA remedy provides a special method and a possible dosing benefit over a Takeda Pharmaceutical product lately authorized on this indication.

The publish Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Uncommon Blood Most cancers appeared first on MedCity Information.

Source link